Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2018

01-02-2018 | Original Paper

LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients

Authors: Jie Zhang, Lei Zhang, Can Li, Caiting Yang, Lili Li, Shushu Song, Hao Wu, Fenglin Liu, Lan Wang, Jianxin Gu

Published in: Cellular Oncology | Issue 1/2018

Login to get access

Abstract

Purpose

Pancreatic cancer (PC) is an aggressive type of cancer that exhibits a rapid progression. Previously LOX-1, which is a type II trans-membrane glycoprotein that is expressed in endothelial cells, has been found to be involved in the development of several types of cancer. As yet, however, the expression of LOX-1 and its functional consequences in PC have not been documented. The present study was aimed at investigating the prognostic relevance of LOX-1 expression in PC patients and at resolving its role in PC metastasis.

Methods

LOX-1 expression was assessed by immunohistochemistry on a tissue microarray containing samples from 98 PC patients. Kaplan-Meier analyses were performed to compare survival curves, whereas Cox regression analyses were performed to explore the independent prognostic value of LOX-1 expression on the overall survival (OS) of PC patients. Harrel’s concordance index was applied to calculate the predictive accuracy of established models. In addition, in vitro scratch wound healing and Transwell assays were used to assess the effect of LOX-1 expression silencing and over-expression on PC cell migration and invasion, whereas Cell Counting Kit-8 (CCK8) and Flow Cytometry (FCM) assays were used to assess its effects on PC cell proliferation and apoptosis.

Results

We found that LOX-1 is highly expressed in the PC tumor tissues tested and is related to the occurrence of lymph node metastases, higher TNM stages and a poor OS. We also found that LOX-1 expression may serve as an independent prognostic factor for the OS of PC patients. Our in vitro assays revealed that LOX-1 expression may promote the migration and invasion of PC cells through epithelial-mesenchymal transition (EMT). No effect on PC cell proliferation was noted.

Conclusions

From our data we conclude that a high LOX-1 expression in PC tissues is indicative for the occurrence of lymph node metastases, high TNM stages and a poor prognosis. LOX-1 may serve as an independent prognostic biomarker. Our in vitro assays additionally revealed that LOX-1 may enhance the migration and invasion of PC cells through EMT. LOX-1 may also serve as a novel therapeutic target.
Appendix
Available only for authorised users
Literature
1.
2.
3.
A. Makohon-Moore, C.A. Iacobuzio-Donahue, Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer 16, 553–565 (2016)CrossRefPubMedPubMedCentral
4.
V. Taucher, H. Mangge, J. Haybaeck, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell. Oncol. 39, 295–318 (2016)CrossRef
5.
M. Giulietti, G. Occhipinti, G. Principato, F. Piva, Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell. Oncol. 39, 379–388 (2016)CrossRef
6.
M.S. Gilardini Montani, M. Granato, C. Santoni, P. Del Porto, N. Merendino, G. D'Orazi, A. Faggioni, M. Cirone, Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell. Oncol. 40, 167–180 (2017)CrossRef
7.
S. Mitra, T. Goyal, J.L. Mehta, Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc. Drugs Ther. 25, 419–429 (2011)CrossRefPubMed
8.
T. Sawamura, N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aiba, T. Tanaka, S. Miwa, Y. Katsura, T. Kita, T. Masaki, An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73–77 (1997)CrossRefPubMed
9.
R. Yoshimoto, Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, T. Sawamura, The discovery of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 25, 379–391 (2011)CrossRefPubMedPubMedCentral
10.
N. Inacio Pinto, J. Carnier, L.M. Oyama, J.P. Otoch, P.S. Alcantara, F. Tokeshi, C.M. Nascimento, Cancer as a Proinflammatory environment: metastasis and cachexia. Mediat. Inflamm. 2015, 791060 (2015)CrossRef
11.
L. Tao, J.Y. Park, J.D. Lambert, Differential prooxidative effects of the green tea polyphenol, (−)-epigallocatechin-3-gallate, in normal and oral cancer cells are related to differences in sirtuin 3 signaling. Mol. Nutr. Food Res. 59, 203–211 (2015)CrossRefPubMed
12.
L. Cominacini, A.F. Pasini, U. Garbin, A. Davoli, M.L. Tosetti, M. Campagnola, A. Rigoni, A.M. Pastorino, V. Lo Cascio, T. Sawamura, Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275, 12633–12638 (2000)CrossRefPubMed
13.
H. Yoshitomi, S. Kobayashi, M. Ohtsuka, F. Kimura, H. Shimizu, H. Yoshidome, M. Miyazaki, Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 37, 275–281 (2008)CrossRefPubMed
14.
H.A. Hirsch, D. Iliopoulos, A. Joshi, Y. Zhang, S.A. Jaeger, M. Bulyk, P.N. Tsichlis, X. Shirley Liu, K. Struhl, A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17, 348–361 (2010)CrossRefPubMedPubMedCentral
15.
M. Khaidakov, S. Mitra, B.Y. Kang, X. Wang, S. Kadlubar, G. Novelli, V. Raj, M. Winters, W.C. Carter, J.L. Mehta, Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS One 6, e20277 (2011)CrossRefPubMedPubMedCentral
16.
F. Wan, X. Qin, G. Zhang, X. Lu, Y. Zhu, H. Zhang, B. Dai, G. Shi, D. Ye, Oxidized low-density lipoprotein is associated with advanced-stage prostate cancer. Tumour Biol. 36, 3573–3582 (2015)CrossRefPubMed
17.
M. Murdocca, R. Mango, S. Pucci, S. Biocca, B. Testa, R. Capuano, R. Paolesse, M. Sanchez, A. Orlandi, C. di Natale, G. Novelli, F. Sangiuolo, The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer. Oncotarget 7, 14765–14780 (2016)CrossRefPubMedPubMedCentral
18.
L. Jiang, S. Jiang, Y. Lin, H. Yang, Z. Zhao, Z. Xie, Y. Lin, H. Long, Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer. Oncotarget 6, 22072–22080 (2015)PubMedPubMedCentral
19.
L. Wang, J. Yin, X. Wang, M. Shao, F. Duan, W. Wu, P. Peng, J. Jin, Y. Tang, Y. Ruan, Y. Sun, J. Gu, C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology 150, 1183–1195 (2016)CrossRefPubMed
20.
X.P. Chen, G.H. Du, Lectin-like oxidized low-density lipoprotein receptor-1: protein, ligands, expression and pathophysiological significance. Chin. Med. J. 120, 421–426 (2007)PubMed
21.
22.
Y. Delneste, G. Magistrelli, J. Gauchat, J. Haeuw, J. Aubry, K. Nakamura, N. Kawakami-Honda, L. Goetsch, T. Sawamura, J. Bonnefoy, P. Jeannin, Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17, 353–362 (2002)CrossRefPubMed
23.
D.P. Ryan, T.S. Hong, N. Bardeesy, Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039–1049 (2014)CrossRefPubMed
24.
Z. von Marschall, T. Cramer, M. Hocker, R. Burde, T. Plath, M. Schirner, R. Heidenreich, G. Breier, E.O. Riecken, B. Wiedenmann, S. Rosewicz, De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119, 1358–1372 (2000)CrossRef
25.
Y. Matsuo, P.M. Campbell, R.A. Brekken, B. Sung, M.M. Ouellette, J.B. Fleming, B.B. Aggarwal, C.J. Der, S. Guha, K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol. Cancer Res. 7, 799–808 (2009)CrossRefPubMedPubMedCentral
26.
X.Z. Zou, Z.C. Gong, T. Liu, F. He, T.T. Zhu, D. Li, W.F. Zhang, J.L. Jiang, C.P. Hu, Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/TGF-beta1/KLF6 signaling pathway in diabetic pulmonary fibrosis. Pulm. Pharmacol. Ther. 44, 70–77 (2017)CrossRefPubMed
27.
B.N. Smith, N.A. Bhowmick, Role of EMT in metastasis and therapy resistance. J. Clin. Med. 5, (2016)
28.
K.J. Woollard, D.C. Phillips, H.R. Griffiths, Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin. Exp. Immunol. 130, 256–262 (2002)CrossRefPubMedPubMedCentral
29.
T. Fu, J. Borensztajn, Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem. J. 366, 195–201 (2002)CrossRefPubMedPubMedCentral
30.
L. Li, N. Roumeliotis, T. Sawamura, G. Renier, C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ. Res. 95, 877–883 (2004)CrossRefPubMed
31.
X.Q. Zhao, M.W. Zhang, F. Wang, Y.X. Zhao, J.J. Li, X.P. Wang, P.L. Bu, J.M. Yang, X.L. Liu, M.X. Zhang, F. Gao, C. Zhang, Y. Zhang, CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J. Lipid Res. 52, 923–933 (2011)CrossRefPubMedPubMedCentral
32.
O. Hofnagel, B. Luechtenborg, K. Stolle, S. Lorkowski, H. Eschert, G. Plenz, H. Robenek, Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24, 1789–1795 (2004)CrossRefPubMed
33.
C. Li, G. Zhao, C. Che, J. Lin, N. Li, L. Hu, N. Jiang, Y. Liu, The role of LOX-1 in innate immunity to aspergillus fumigatus in corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 56, 3593–3603 (2015)CrossRefPubMed
34.
H. Sawai, H. Funahashi, Y. Okada, Y. Matsuo, M. Sakamoto, M. Yamamoto, H. Takeyama, T. Manabe, Interleukin-1alpha enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Med. Sci. Monit. 11, BR343–BR350 (2005)PubMed
35.
Y. Zhang, W. Yan, M.A. Collins, F. Bednar, S. Rakshit, B.R. Zetter, B.Z. Stanger, I. Chung, A.D. Rhim, M.P. di Magliano, Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73, 6359–6374 (2013)CrossRefPubMed
36.
M.D. Barber, J.J. Powell, S.F. Lynch, K.C. Fearon, J.A. Ross, A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer 83, 1443–1447 (2000)CrossRefPubMedPubMedCentral
Metadata
Title
LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients
Authors
Jie Zhang
Lei Zhang
Can Li
Caiting Yang
Lili Li
Shushu Song
Hao Wu
Fenglin Liu
Lan Wang
Jianxin Gu
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0360-6

Other articles of this Issue 1/2018

Cellular Oncology 1/2018 Go to the issue

Original Paper

Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma

Report

Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report

Letter to the Editor

Metabolic iodine and tumours

Original Paper

Memory CD4+ T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells

Original Paper

A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation

Original Paper

Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits